Author information: (1)New York University Langone Health and The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York, NY, USA. (2)Vaccinex, Inc., Research, Rochester, NY, USA. (3)IXICO, London, UK. (4)WCG Statistics Collaborative, Inc., Washington, DC, USA. (5)University of Rochester Medical Center, Rochester, NY, USA. (6)Siemers Integration LLC, Zionsville, IN, USA. (7)Vaccinex, Inc., Research, Rochester, NY, USA. mzauderer@vaccinex.com.

Author information: (1)Biogen, Cambridge, MA, USA. tien.dam@biogen.com. (2)Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA. (3)Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. (4)Department of Neurology, Technische Universität München, Munich, Germany. (5)German Center for Neurodegenerative Diseases, Munich, Germany. (6)Department of Neurology, Hanover Medical School, Hanover, Germany. (7)National Hospital for Neurology and Neurosurgery, London, UK. (8)University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA. (9)Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada. (10)Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France. (11)Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan. (12)Global R&D Partners, LLC, San Diego, CA, USA. (13)Biogen, Cambridge, MA, USA.